Specialized Cancer Center Support Grant

专门癌症中心支持补助金

• 批准号: 8666263
• 负责人: SCOTT M LIPPMAN
• 金额: $ 373.05万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-07-01 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8666263
• 关键词: Academia; Basic Science; Bioinformatics; Biological Sciences; Biometry; Biotechnology; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Caring; Clinical; Clinical Sciences; Collaborations; Comprehensive Cancer Center; Detection; Diet; Direct Costs; Division of Basic Sciences; Environment; Flow Cytometry; Funding; Genomics; Goals; Hematologic Neoplasms; Industry; Institutes; Investments; Journals; Malignant Neoplasms; Medicine; Microscopy; Mission; Organizational Change; Paper; Peer Review; Physical activity; Physicians; Population Sciences; Private Sector; Public Sector; Publishing; Recording of previous events; Reporting; Research; Research Institute; Research Personnel; Resource Sharing; Resources; Science; Scientist; Signal Transduction; Site; Solid Neoplasm; Source; Technology; Therapeutic; Tissues; Transgenic Mice; Translations; Universities; Vision; base; biobank; cancer genome; cancer health disparity; cancer prevention; cancer therapy; design; innovation; interdisciplinary collaboration; member; programs

DESCRIPTION (provided by applicant): The UC San Diego (UCSD) Moores Cancer Center (MCC) has a rich history as a matrix, NCI-designated comprehensive cancer center, now with 239 members from 28 UCSD departments. Peer-reviewed MCC funding is $118.3 million (direct costs), of which $33.2 million is from the NCI. An additional $15.6 million from non-peer-reviewed sources results in total direct-cost funding of $133.9 million. We have published over 4000 cancer-focused papers in the funding period (20% inter- or intra-programmatic; 10% in journals with an impact factor >15). MCC is surrounded by several other major life-science research institutes and 489 biotechnology companies in San Diego/La Jolla, the 2"'' largest life-sciences cluster in the US. MCC is the only NCI-designated comprehensive cancer center in this region. MCC leverages this advantage to save lives by transforming cancer prevention, detection, and care (mission) and to make personalized cancer medicine a reality (vision). This is our first renewal application as a consortium center with partner San Diego State University (SDSU), thus formalizing long-standing, productive collaborations between MCC and SDSU. As designed, the MCC building 1) stimulates interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Basic Science, Clinical Science, and Population Science, 2) assembles the extensive NCI-supported Shared Resources in a common, accessible site, and 3) acts as an academia-industry hub for translational cancer researchers within the public and private sectors of San Diego. The vast majority of members are in the MCC building or on the UCSD campus; others are in nearby La Jolla institutes. This application reports on six Research Programs: Cancer Biology and Signaling, Cancer Genomes and Networks, Hematologic Malignancies, Solid Tumor Therapeutics, Cancer Prevention, and Reducing Cancer Disparities. We also propose seven Shared Resources: Biorepository and Tissue Technology, Biostatistics, Genomics and Bioinformatics, Microscopy, Flow Cytometry, Transgenic Mouse, Diet and Physical Activity. All Programs and Resources reflect the scientific strengths and goals of the MCC. MCC is poised to leverage its exceptional basic and population sciences and San Diego-wide collaborations (academic and private-sector) in developing innovative science-based cancer prevention and treatment. This application summarizes our investments, recruitments, collaborations, organizational changes, plans, and progress toward this goal. CCSG funding advances the UCSD Moores Cancer Center mission to save lives by transforming cancer prevention, detection, and care, and vision to make personalized cancer medicine a reality. The Cancer Center places the highest priority on basic discovery and its translation (via leveraging San Diego's unique academia-industry environment) into major clinical advances that reduce the burden of cancer.

描述（由申请人提供）：加州大学圣地亚哥分校 (UCSD) 摩尔斯癌症中心 (MCC) 作为矩阵、NCI 指定的综合癌症中心拥有丰富的历史，目前拥有来自 28 个 UCSD 科室的 239 名成员。经同行评审的 MCC 资金为 1.183 亿美元（直接成本），其中 3320 万美元来自 NCI。来自非同行评审来源的额外 1,560 万美元导致直接成本资金总额为 1.339 亿美元。在资助期内，我们发表了 4000 多篇以癌症为主题的论文（20% 是项目间或项目内的；10% 发表在影响因子 >15 的期刊上）。 MCC 周围还有圣地亚哥/拉霍亚的其他几家主要生命科学研究机构和 489 家生物技术公司，是美国第二大生命科学集群。MCC 是该地区唯一一家 NCI 指定的综合性癌症中心MCC 利用这一优势，通过改变癌症预防、检测和护理（使命）并使个性化癌症医学成为现实（愿景），这是我们与合作伙伴圣地亚哥州立大学联合中心的第一个更新应用。 (SDSU)，从而使 MCC 和 SDSU 之间的长期、富有成效的合作正式化。按照设计，MCC 大楼 1) 促进了中心基础科学、临床科学和人口科学部门的医生和科学家之间的跨学科合作，2) 聚集。 NCI 支持的广泛共享资源位于一个公共、可访问的站点，3) 充当圣地亚哥公共和私营部门转化癌症研究人员的学术界和工业中心。绝大多数会员都在MCC大楼或UCSD校园内；其他人在附近的拉霍亚研究所。该申请报告了六个研究项目：癌症生物学和信号转导、癌症基因组和网络、血液恶性肿瘤、实体瘤治疗、癌症预防和减少癌症差异。我们还提出了七个共享资源：生物样本库和组织技术、生物统计学、基因组学和生物信息学、显微镜、流式细胞术、转基因小鼠、饮食和体育活动。所有计划和资源都反映了 MCC 的科学优势和目标。 MCC 准备利用其卓越的基础科学和人口科学以及圣地亚哥范围内的合作（学术和私营部门）来开发基于科学的创新癌症预防和治疗。该应用程序总结了我们的投资、招聘、合作、组织变革、计划和实现这一目标的进展。 CCSG 的资助推进了加州大学圣地亚哥分校摩尔斯癌症中心的使命，即通过改变癌症预防、检测和护理来拯救生命，并实现个性化癌症医学的愿景。癌症中心将基础发现及其转化（通过利用圣地亚哥独特的学术界和工业环境）转化为减轻癌症负担的重大临床进展为重中之重。